Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAS
NCT03759938Phase 4Active, not recruiting
- Sponsor
- University College London
- Start
- Jun 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of apixaban, dabigatran etexilate oral solution, edoxaban, rivaroxaban in Atrial fibrillation (AFib), ischemic stroke, sponsored by University College London. Started Jun 2019; status: active, not recruiting.
02
Drugs
apixabandabigatran etexilate oral solutionedoxabanrivaroxaban
03
Conditions
Atrial fibrillation (AFib)ischemic stroke
Beyond the preview
Go deeper on NCT03759938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03759938.